You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SapC-DOPS nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within the first year. Clearly, there is an urgent ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Concurrent Upper/Lower Extremity SCI Exercise with Stimulation

    SBC: CUSTOMKYNETICS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): This proposal will develop a FES-augmented recumbent stepper that elicits lower extremity involvement through electrical stimulation while upper extremity involvement is volitionally controlled by the client. Exercise for people with spinal cord injury not only enhances physical fitness but has the potential to slow or reverse many of the secondary complication ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Selection-driven plant metabolites for treatment of CNS diseases

    SBC: NAPROGENIX, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): The primary aim is to transfer a biotechnology platform for plant drug discovery from the academic laboratory to industry use (i.e. this application is directly responsive to the lab to marketplace roadmap program). Many defensive metabolites in plants are targeted on key proteins in the insect CNS, and homology between these and human proteins, makes such ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Injectable collagen crosslink augmentation for degenerative disc disease

    SBC: ORTHOPEUTICS, LP            Topic: NIAMS

    DESCRIPTION (provided by applicant): With regard to prevalence and cost to society, low-back pain has few peers. With a patient population in excess of 15 million/year, the societal cost is estimated to be in the realm of 100 billion/year. Current treatment options for this disease have shown limited success, including physical therapy, medication and surgery. This proposal involves a novel, nons ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. A non-surgical embryo transfer device for producing gene modified rats

    SBC: PARATECHS CORP            Topic: NCRR

    DESCRIPTION (provided by applicant): Rats represent the most commonly used physiologically and pharmacological experimental model for studying human disease. The ability to genetically modify rats through methods of gene transfer in fertilized rat embryos or by gene targeting in embryonic stem (ES) cells has significantly increased the capabilities of rats in biomedical and pharmaceutical research ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Novel methods for improving virion production in baculovirus

    SBC: PARATECHS CORP            Topic: NIGMS

    DESCRIPTION (provided by applicant): Baculovirus expression vectors have been successfully used to produce thousands of proteins for vaccines, therapeutics, and structure-function studies. Baculoviruses have also been adapted for use as mammalian expression systems and potential gene therapy agents. This proposal explores a novel strategy for purification, quantitation, and storage of high titer b ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing mammalian glycoprotein production in the baculovirus expression vector

    SBC: PARATECHS CORP            Topic: NIGMS

    DESCRIPTION (provided by applicant): The baculovirus expression vector system (BEVS) is a proven, powerful and versatile method of eukaryotic protein expression. It is used to produce vaccines, diagnostics, and biologically active proteins for a multitude of research projects. Like all expression systems, however, BEVS has its disadvantages. One is the fact that expression is short-lived due to vi ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Personalized Medicine Interface for the Safe and Effective Treat

    SBC: PHARMACOGENETICS DIAGNOSTIC LABORATORIES            Topic: NHLBI

    DESCRIPTION (provided by applicant): Improvements in the safety and efficacy of warfarin therapy will result from intelligent application of knowledge derived from inherited characteristics (CYP2C9 and VKORC1) of individual patients, only when this knowledge is applied through a standardized interventional approach. The fundamental pharmacologic influences of CYP2C9 and VKORC1 have been unequi ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Counterpulsation Device with Integrated ECG Sensing

    SBC: SCR, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Counterpulsation with an intra-aortic balloon pump has been widely and successfully used as a short term treatment for both acute and chronic cardiac dysfunction. SCR (Louisville, KY) is developing a novel chronic, implantable counterpulsation device (CPD) to treat late stage HF patients. The CPD is a 32-ml stroke volume polyurethane-lined blood chamber design ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Generation of Site-Specific Recombinase-Expressing Transgenic Rats using an Enhan

    SBC: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.            Topic: NHGRI

    DESCRIPTION (provided by applicant): The goal is to create site-specific recombinase (SSR)-expressing transgenic rats in an efficient and unbiased manner through a transposon-mediated in vivo gene trap. Rats are very relevant for modeling human biology and disease because rats, unlike mice, possess key biological similarities to humans. While in vitro gene trap mutagenesis is useful for gene d ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government